Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-10T07:21:50.608Z Has data issue: false hasContentIssue false
  • English
  • Français

Precision Medicine & Pharmacogenomics: Personalized Medication in Neuropsychiatric Disorders using AI and telepsychiatry

Published online by Cambridge University Press:  01 September 2022

N. Gkouvas
N. Gkouvas*
Affiliation:
Hellenic Psychiatric Association, Board Member, Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The term “personalised therapy” refers to the use of genetic data to better treat or determine the predisposition to a specific genetic disease, with the ultimate goal of improving quality of life. Telepsychiatry and AI are key to support it..

Objectives

Determine benefits of pharmacogenomic analysis (PGx) in CNS diseases regarding: - cost effectiveness - adverse drug reactions - reduced hospitalizations -drug interactions - efficacy - quality of life - “trial and error” approach avoidance

Methods

Questionnaires before and after the treatment provided using PGX tests Telepsychiatry for consultation along face to face sessions were conducted. Artificial intelligence in data analyses

Results

Benefits of pharmacogenomic analysis (PGx) in CNS diseases: - cost effective savings - prediction and prevention of adverse drug reactions - reduced hospitalization due to ineffectiveness of medication - reduced risk of drug interactions - more effective treatments - better quality of life for the patient - with the analysis (PGx) the “trial and error” approach is avoided

Conclusions

In a number of studies in patients with mental disorders, pharmacogenomic analysis (PGx) has led to an increase in both clinical response and remission, better tolerated treatments, fewer side effects, and reduced treatment costs. In conclusion, pharmacogenomic analysis is ideal for patients with CNS diseases: a) Not responding to treatment b) Who in their history have many relapses and hospitalizations c) They show serious side effects d) Who do not comply with the treatment e) Taking many medications and suffering from serious illnesses f) Who are wary of taking psychotropic drugs

Disclosure

No significant relationships.

Keywords

Precision Psychiatrye-mental healthtelepsychiatryArtificial intelligence
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S678
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.